Premium
Proliferating cell nuclear antigen and p53 expression as prognostic factors in T1‐2MO prostatic adenocarcinoma
Author(s) -
Vesalainen Satu L. B.,
Lipponen Pertti K.,
Talja Martti T.,
Alhava Esko M.,
Syrjánen Kari J.
Publication year - 1994
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910580226
Subject(s) - proliferating cell nuclear antigen , stromal cell , immunohistochemistry , antigen , cancer research , p53 protein , stage (stratigraphy) , cell , stroma , biology , pathology , medicine , oncology , immunology , paleontology , genetics
The expression of proliferating cell nuclear antigen and p53 protein was analysed by immunocytochemical methods (PC10, CMI antisera) in 139 patients with T1‐2MO prostatic adenocarcinomas followed‐up for > 12 years. p53 protein was expressed in 21 (15%) tumours (15%), the fraction of positive nuclei being very low (mean SE, 1% ± 0.7%). Accumulation of p53 protein in epithelial cells was independent of tumour stage and Gleason score, and had no effect on prognosis. In 4 cases, p53 protein was expressed only in stromal cells. The fraction of PCNA‐positive nuclei (evaluable in 116 cases) was higher in T2 than in T1 tumours ( p < 0.001); furthermore, high Gleason score was positively correlated with PCNA positivity ( p < 0.001). A finding of over 5% of PCNA‐positive nuclei predicted progression in T and M categories and were a sign of poor outcome. The fraction of PCNA‐positive stromal‐cell nuclei was related to T‐category with a borderline significance ( p = 0.06). In a multi‐variate analysis of the prognostic factors, independent predictors of survival included Gleason score ( p < 0.001), fraction of PCNA‐positive nuclei ( p = 0.013), observation before therapy ( p = 0.05), and T‐category ( p = 0.07) in that order of significance. The results suggest that overexpression of p53 protein is of marginal prognostic value in local prostatic adenocarcinomas, whereas direct measurement of cell proliferation by PCNA immunolabelling provides important prognostic information in T1‐2MO tumours, in addition to the Gleason score.